甲福明通过AMPK/Nrf2通路抑制铁亡,减轻糖尿病骨质疏松症
Yanwei Liu1, Zhaoyu Fu2, Xinyu Wang1
1Department of Orthopaedics, The First Hospital of Jilin University, Changchun, China.
Frontiers in pharmacology
|April 10, 2025
概括
甲福明通过抑制铁亡和促进骨质细胞功能来保护糖尿病骨质疏松症. 它激活AMPK/Nrf2通路,在糖尿病骨质疏松症模型中保持骨健康.
科学领域:
- 生物医学科学 生物医学科学
- 细胞生物学 细胞生物学
- 代谢性骨疾病 代谢性骨疾病
背景情况:
- 在骨质疏松症中,铁质显著损害骨质细胞功能.
- 甲胺 (Met) 显示了糖尿病骨质疏松症 (DOP) 的治疗潜力.
- 甲基对骨代谢作用的精确机制尚未完全理解.
研究的目的:
- 调查梅特福林在糖尿病骨质疏松症中的作用.
- 探索梅特福林在DOP中的治疗效果的潜在机制.
主要方法:
- 在体外:骨质细胞被用来评估在高葡萄糖和棕酸条件下甲胺对分化和铁亡的影响.
- 在体内:建立了一种糖尿病骨质疏松症大鼠模型 (高脂肪饮食和链素),以使用微型CT和组织形态学评估Metformin的骨保护作用.
主要成果:
- 甲福明通过增加保护性蛋白质 (GPX4,FTH1,SLAC7A11) 和减少脂质过氧化,抑制了骨质细胞中高葡萄糖/棕酸诱导的铁亡.
- 甲胺增强了骨质生成标志物 (RUNX2,COL1A1) 和骨质细胞中的性酸酶活性.
- 在糖尿病骨质疏松症的小鼠模型中,甲福明激活了AMPK/Nrf2通路,防止了铁亡,并减轻了骨损失和微观结构损伤.
结论:
- 甲福明激活AMPK/Nrf2通路以抑制铁亡.
- 这种机制可以保护糖尿病骨质疏松症,改善骨健康.
更多相关视频
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
798
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
297
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
